The Neurochemistry Core will integrate and consolidate the activities performed in several basic laboratories of this Center into three units, under the direction of Drs Moore, Cooper and Javitch, respectively: 1) In vivo and ex vivo determination of brain catecholamine, indoleamine and amino acid transmitter levels (Moore). This unit will provide logistical support and technical expertise to projects of the Center that employ in vivo microdialysis in rodents and primates (Projects by Laurelle, Kandel, Rayport) including experimental design, implementation, and chromatographic analysis of catecholamines, indolamines and amino acids in in vivo brain dialysate samples and ex vivo brain tissue homogenates (Projects by Laurelle, Javitt, Kandel, Rayport). 2) Pharmacokinetic Unit (Cooper). This unit will develop and perform analysis of plasma levels of pharmacological agents (e.g. MK 801, NNC 112, SCH 39166, amphetamine, PCP, risperidone) used in mice (Projects by Kandel, Rayport ); non-human primates (Projects by Laurelle and Project by Javitt) and humans (Projects by Abi-Dargham and Laurelle). 3) Receptor Binding Unit (Javitch). This unit will integrate activiiies performed in the laboratories of Javitch, Rayport, and Huang. The first mission is to perform in vitro binding assay and to characterize candidate radioligands developed by the Brain Imaging Core and Projects by Abi-Dargham and Project by Laurelle. The second mission is to study the impact of receptor trafficking on binding affinities of D2 and D1 radiotracers. The latter investigation will provide important information for imaging studies using endogenous competition techniques such as used in Project by Laurelle, and will contribute to the development of novel radioligands with binding that is sensitive to changes in synaptic/extracellular concentrations of endogenous transmitters, specifically dopamine and glutamate (see Brain Imaging Core). In summary, the Neurochemistry Core will share personnel and will work closely with Projects by Abi-Dargham, Laurelle, Javitt, Kandel & Rayport and the Brain Imaging Core and Cellular/Molecular Core to provide screening and hypothesis-directed characterization of neurotransmitter profiles in animal models, development of novel methods for combining in vivo microdialysis and functional brain imaging in primates and rodents, and development of methods for characterization of candidate radioligands for functional brain imaging.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
5P50MH066171-03
Application #
7248770
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
3
Fiscal Year
2006
Total Cost
$179,644
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Slifstein, Mark; van de Giessen, Elsmarieke; Van Snellenberg, Jared et al. (2015) Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72:316-24
Chuhma, Nao; Mingote, Susana; Moore, Holly et al. (2014) Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron 81:901-12
Poels, E M P; Kegeles, L S; Kantrowitz, J T et al. (2014) Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 19:20-9
Poels, Eline M P; Kegeles, Lawrence S; Kantrowitz, Joshua T et al. (2014) Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 152:325-32
Poels, Eline M P; Girgis, Ragy R; Thompson, Judy L et al. (2013) In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia. Psychopharmacology (Berl) 228:167-74
Kisby, Glen E; Moore, Holly; Spencer, Peter S (2013) Animal models of brain maldevelopment induced by cycad plant genotoxins. Birth Defects Res C Embryo Today 99:247-55
Mihali, Andra; Subramani, Shreya; Kaunitz, Genevieve et al. (2012) Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. Expert Rev Neurother 12:785-99
Ward, Ryan D; Simpson, Eleanor H; Richards, Vanessa L et al. (2012) Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia. Neuropsychopharmacology 37:1699-707
Abi-Dargham, Anissa; Xu, Xiaoyan; Thompson, Judy L et al. (2012) Increased prefrontal cortical D? receptors in drug naive patients with schizophrenia: a PET study with [¹¹C]NNC112. J Psychopharmacol 26:794-805
Li, Yan-Chun; Kellendonk, Christoph; Simpson, Eleanor H et al. (2011) D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortex. Proc Natl Acad Sci U S A 108:12107-12

Showing the most recent 10 out of 31 publications